

REMARKS**Amendments to the Claims**

Claims 48-103 are pending. The Applicants respectfully ask the Examiner to replace all prior versions and listings of claims in the present application with the listing of claims currently provided. Claims 48, 50, 53-55, 57-62, 69, 70, 73 and 75 were amended, Claims 49, 51, 52, 56, 63-68, 71, 72, 74 and 76-103 were canceled in accordance to the restriction requirement.

Restriction Requirement

The Examiner has restricted the present application under PCT Rule 13.1 as allegedly disclosing four independent and distinct inventions designated Group I (Claims 48, 50-77, 79-85), Group II (Claims 49, 51-76, 78-85), Group III (Claims 86-93, 102) and Group IV (Claims 94-103). The Applicants elect to prosecute Examiner's Group I (Claims 48, 50-77, 79-85).

The Examiner has further restricted Group I or Group II under PCT Rule 13.1 as allegedly lacking unity of invention that requires selection of a species from each of three Species groups: Species A (SNAP-25, Syntaxin 1, Synaptobrevin), Species B (polypeptide, polynucleotide) and Species C (nerve cell, insulin-secreting cell). The Applicants elect to prosecute SNAP-25, polypeptide and nerve cell.

CONCLUSION

For the above reasons the Applicants respectfully submit that the claims are in condition for allowance, and the Applicants respectfully urge the Examiner to issue a Notice to that effect. Should there be any questions, the Examiner is invited to call the undersigned agent. Please use Deposit Account 01-0885 for the payment of any extension of time fees under 37 C.F.R. § 1.136 or any other fees due in connection with the current response.

Respectfully submitted,

/Dean G. Stathakis/

Dean G. Stathakis, Ph.D.
Registration No. 54,465
Agent of Record



ALLERGAN

LEGAL DEPARTMENT

2525 Dupont Drive
Irvine, California 92612-1599
Tel: 714/246-6521
Fax: 714/246-4249